DOI: 10.3724/SP.J.1123.2019.07002

Chinese Journal of Chromatography (色谱) 2019/37:12 PP.1297-1304

A high-performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of four genotoxic impurities in gefitinib

In this work, a method for the determination of the amounts of the four genotoxic impurities in gefitinib has been developed. A simple and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) approach has been developed, optimized, and validated. The genotoxic impurities were 3-chloro-4-fluoroaniline, 3,4-difluoroaniline, 3-fluoro-4-chloroaniline, and 3,4-dichloroaniline. Separation was achieved on an Inertsil ODS-3 column (100 mm×3.0 mm, 3 μm). The column temperature was 40 ℃, and the running time was 12 min. A triple quadrupole mass detector with positive electrospray ionization in the multiple reaction monitoring (MRM) mode was applied. The method was validated in terms of its specifi-city, linearity, precision, accuracy, stability, and robustness. The correlation coefficient of each impurity was higher than 0.999 in the range of 0.6-96.0 μg/L. The limits of detection (LODs) and limits of quantity (LOQs) were in the ranges of 0.2-2.0 μg/L and 0.6-6.0 μg/L, respectively. The recoveries of all impurities at 6, 30, and 60 μg/L were within 91.0%-98.5%. All impurities were stable within 2 h. After detection, only 3-chloro-4-fluoroaniline was detected in the batch number 16052301 and R16052501-1 gefitinib samples, but its concentration was below the impurity limit (6 mg/L). This method is simple, reliable, and suitable for the determination of four genotoxic impurities in gefitinib. It can be further applied as a reference for quality control.

Key words:high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS),genotoxic impurity,gefitinib

ReleaseDate:2019-12-02 10:05:18

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Int J Cancer, 2015, 136(5):E359

[2] Tamura K, Fukuoka M. EOP, 2005, 6(6):985

[3] Martens U M. Small Molecules in Oncology. 3rd ed. Cham:Springer International Publishing AG, 2018:235

[4] Fang L, Song Y, Weng X, et al. BMC, 2015, 29(12):1937

[5] Lemmon M A, Schlessinger J. Cell, 2010, 141(7):1117

[6] Li M D, Zheng Y G, Ji M. Molecules, 2007, 12(3):673

[7] Guan Z Z, Zhang L, Li L Y, et al. CJC, 2005, 24(8):980

[8] Li J K, Wang S S, Chen X F, et al. Life Science Instrument, 2017, 1:50

[9] Yang Q Y, Xu G C, Chen L K. Chinese Journal of Neurological Oncology, 2004, 3:197

[10] Wang S S, Ning F S, Li X L, et al. JPA, 2017, 37:1309

[11] Wu X H, Luo A, Ye L B, et al. Journal of Instrumental Analysis, 2016, 35(1):35

[12] Bouder F. Expert Rev Clin Pharmacol, 2008, 1(2):241

[13] Mueller L, Mauthe R J, Riley C M, et al. Regul Toxicol Pharmacol, 2006, 44(3):1

[14] European Medicines Agency Evaluation of Medicines for Human Use (EMEA). Committee for Medicinal Products for Human Use time (CHMP) Guidelines on the Limits of Genotoxic Impurities (CPMP/SWP/5199/02). (2006-06-28)[2019-06-28].

[15] Liu X W, Li C, Han Y H, et al. Chinese Journal of Chromatography, 2018, 36(10):952

[16] U S Food and Drug Administration. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER) Guidance for industry. Genotoxic and Carcinogenic Impurities in Drug Substances and Products:Recommended Approaches (Draft).[2019-06-28].

[17] China Food and Drug Administration. Pharmacopoeia of the People's Republic of China. (2015-06-05)[2019-06-28].

[18] ICH.M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. (2014-06-23)[2019-06-28].

[19] Xie W F, Gao Y Z, Tang X X. JPA, 2018, 38(12):2110

[20] Yuan Q Y, Li C, Li J C, et al. Chinese Journal of Modern Applied Pharmacy, 2017, 34(3):407

[21] Xu J. JPA, 2017, 37(1):105

[22] Luan B L, Xu X J, Liang G T, et al. Journal of China Pharmaceutical University, 2019, 50(3):325

[23] Hou J F, Li M, Qi L, et al. China Medical Herald, 2018, 15(3):126